Asset profile

Lenalidomide

Small molecule

ApprovedUndisclosed / early pipelineCereblon E3 ubiquitin-ligase
Approvedregulatory verdict

Evidence outlook

Approved — Multiple Myeloma

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Upcoming events

(80 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (12)
September 2026 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-09 · NCT05690984 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (4)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-10 · NCT03004287 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-10-07 · NCT03993912 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-10-20 · NCT06140966 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-10-31 · NCT05573802 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06517017 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-19 · NCT04174196 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (4)
Phase 2Myeloma, MultipleActive not recruiting
Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-12-01 · NCT04876248 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (20)
February 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (4)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Hematopoietic Cell Transplantation Recipient, Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-04-30 · NCT02420860 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-11 · NCT02659293 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaEnrolling by invitation
Est. primary completion 2027-11-30 · NCT07210047 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (8)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT04891809 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT06461988 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03376672 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05776979 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05091372 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (12)
January 2028 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT06744894 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-04 · NCT05243797 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-05 · NCT07485647 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (2)
Phase 2Malignant Plasma Cell NeoplasmsNot yet recruiting
Est. primary completion 2028-06 · NCT07560449 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-06 · NCT03617731 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2028-10-11 · NCT07735637 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)
Phase 2Plasma Cell MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)
Phase 3DLBCL - Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2028-12-15 · NCT06220032 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (10)
January 2029 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2029 (2)
Phase 3Cutaneous Lupus Erythematosus (CLE)Not yet recruiting
Est. primary completion 2029-02-01 · NCT06965244 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-02-14 · NCT04923893 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2029 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2029-04 · NCT04822337 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)
Phase 2Plasma Cell Leukemia (PCL)Not yet recruiting
Est. primary completion 2029-06-30 · NCT07652905 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-07-01 · NCT04071457 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-08 · NCT03948035 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT06207799 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Smoldering Plasma Cell MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT03937635 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (8)
April 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-04-01 · NCT07029776 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-09-30 · NCT06997081 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2030 (2)
Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2030-10-14 · NCT04270409 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting
Est. primary completion 2030-10-18 · NCT05623020 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-11-30 · NCT06931704 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-12 · NCT05344833 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (6)
January 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-01 · NCT06187441 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2031 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2031-02-14 · NCT07671287 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2031 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-28 · NCT06679101 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-30 · NCT05552222 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2031 (1)
Phase 3Plasma Cell MyelomaRecruiting
Est. primary completion 2031-05-30 · NCT05561387 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-11 · NCT07285239 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (4)
January 2032 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2032-01-31 · NCT06182774 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2032 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-11 · NCT06974786 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2032 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-12-02 · NCT06910124 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (3)
May 2033 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2033-05-28 · NCT05145400 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2033 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-06 · NCT07649525 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (1)
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2036 (3)
May 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2036 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-12 · NCT06932562 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2042 (1)
January 2042 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2042-01 · NCT07095452 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.

Educational data tool. Grades describe evidence quality, not investment merit.